By Daniella Parra
NANO-X IMAGING LTD (Nasdaq: NNOX) has integrated FDA-cleared AI solutions into its Second Opinions online consultation service, offered by its subsidiary, USARAD Holdings INC, the company said.
This platform connects patients with specialists for additional diagnostic consultations, it said.
The AI tools for early detection of chronic conditions through CT scans include detection of early signs of coronary artery disease, bone mineral density to highlight osteoporosis risks, and liver density to indicate fatty liver disease, the company said.
“We will continue exploring opportunities to leverage our AI technology to promote accessible early diagnosis and preventative management,” Erez Meltzer, Nanox Chief Executive Officer, said.